CytoSorbents Reports Third Quarter 2023 Financial and Operat

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood

Related Keywords

New Jersey , United States , State Of New Jersey , Germany , Canada , New York , Canadian , American , Kathleen Bloch , James Komsa , Irina Kulinets , Vincent Capponi , Phillip Chan , Efthymios Deliargyris , National Institutes Of Health , National Heart , Fresenius Medical Care , Human Services , Facebook , Material Command , Astrazeneca , Bus Company Contact , Us Army , Fresenius , Cytosorbents Corporation , Twitter , Medtronic , Pfizer , Vascular Group , Development Expenses , European Union , Us Department Of Health , Blood Institute , Us Centers Of Medicare Medicaid Services , Company Board Of Directors , Us Air , Health Canada , Sorbents Corporation , Operating Highlights , Chief Executive Officer , Timely Antithrombotic Removal , Safety Monitoring Board , Global Regulatory , Device Designation , Cleveland Clinic , American Journal , Cardiovascular Drugs , Serious Complication , Quality Star Rating , Medicaid Services , Chief Operating Officer , Chief Medical Officer , Vice President , Northeast Cardiac , Critical Care , Blood Purification , Medical Care , Acute Therapies , Renal Therapies , Administrative Expenses , Foreign Currency Transactions , Capital Resources , Call Details , Presentation Webcast , Investor Relations , Use Authorization , Device Designations , Timely Antithrombotic Removal Ticagrelor , National Institutes , Operations Command , Air Force Material Command , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Region ,